Last quarter (Q3 2023), Sagimet Biosciences, Inc. Class A's total revenue was $2.00M, an increase of Infinity% from previous quarter. In Q3, Sagimet Biosciences, Inc. Class A's net income was $-6.35M. See Sagimet Biosciences, Inc. Class A’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21
Total Revenue	$ 2.00M	-	-
Cost of Revenue	-	-	-
Gross Profit	$ 2.00M	-	-
Operating Expense	$ 16.51M	$ 31.05M	-
Operating Income	$ -14.51M	$ -31.05M	-
Net Non Operating Interest Income Expense	$ 1.37M	$ 553.00K	-
Other Income Expense	$ -5.00K	$ -3.00K	-
Pretax Income	$ -13.14M	$ -30.50M	-
Tax Provision	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-
Net Income Common Stockholders	$ -13.14M	$ -30.50M	-
Basic EPS	$ -35.80	$ -165.20	-
Diluted EPS	$ -35.80	$ -165.20	-
Basic Average Shares	$ 189.52K	$ 184.62K	-
Diluted Average Shares	$ 189.52K	$ 184.62K	-
Dividend Per Share	-	-	-
Total Operating Income As Reported	-	-	-
Reported Normalized Basic E P S	-	-	-
Reported Normalized Diluted E P S	-	-	-
Rent Expense Supplemental	-	-	-
Total Expenses	$ 16.51M	$ 31.05M	$ 23.72M
Net Income From Continuing And Discontinued Operation	$ -13.14M	$ -30.50M	-
Normalized Income	$ -5.36M	-	-
Interest Expense	-	-	-
EBIT	$ -6.79M	-	-
EBITDA	-	-	-

Currency in USD

Sagimet Biosciences, Inc. Class A Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing